Sarepta Therapeutics Inc. shares fell in the extended session Monday after the drug maker said the Food and Drug Administration raised concerns about its...
Sarepta Therapeutics Inc.
shares fell in the extended session Monday after the drug maker said the Food and Drug Administration raised concerns about its muscular dystrophy treatment. Sarepta shares fell 12% after hours, following a 3.7% decline in the regular session to close at $120.31. The FDA cited a risk of infections in the intravenous sites where the drug was administered and concerns about kidney toxicity.
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
A $1,500 drug that claims to cure jet lag has been held held up by the FDAAt $1,500 for a three-day dosage, the drug might not be worth the cost, if it is ever approved by federal regulators.
Leer más »
A $1,500 drug that claims to cure jet lag has been held held up by the FDAAt $1,500 for a three-day dosage, the drug might not be worth the cost, if it is ever approved by federal regulators.
Leer más »
Intestinal Illness Linked to Imported Fresh BasilCONSUMER ALERT: An outbreak of intestinal illness -- which officials believe may be caused by fresh basil imported from Mexico -- is linked to 205 illnesses across 11 states, including 5 hospitalizations.
Leer más »
Why a Yield-Curve Inversion May Be Good News for This Lagging Stock SectorLast week’s yield-curve inversion might have been a good sign for the stock market’s biggest laggard this year: energy stocks.
Leer más »
UK minister dismisses 'scaremongering' over leaked Brexit reportBritish energy minister Kwasi Kwarteng on Sunday dismissed concerns over potenti...
Leer más »
UK minister dismisses 'scaremongering' over leaked Brexit reportBritish energy minister Kwasi Kwarteng on Sunday dismissed concerns over potenti...
Leer más »